BRIEF published on 08/11/2026 at 18:35, 3 months ago Medincell at Piper Sandler CNS Symposium 2026 Investors Medincell BEPO Technology Piper Sandler CNS Symposium Prolonged Treatments
BRIEF published on 08/11/2026 at 18:35, 3 months ago Medincell au Piper Sandler CNS Symposium 2026 Investisseurs Medincell Piper Sandler CNS Symposium BEPO Technologie Traitements Prolongés
PRESS RELEASE published on 08/11/2026 at 18:30, 3 months ago Informations privilégiées / Autres communiqués Medincell participera au Piper Sandler CNS Symposium le 13 août 2026 avec le Dr Grace Kim, CSO, U.S. Finance. L'entreprise développe des traitements injectables à action prolongée pour divers domaines thérapeutiques Medincell Dr Grace Kim Action Prolongée Piper Sandler CNS Symposium Traitements Injectables
BRIEF published on 07/29/2026 at 13:29, 3 months 13 days ago Medincell Partner Teva Reports Strong UZEDY® Sales Growth Net Sales Growth Revenue Outlook Schizophrenia Treatment Teva Pharmaceuticals Long-acting Injectable
BRIEF published on 07/29/2026 at 13:29, 3 months 13 days ago Record sales for UZEDY® in the second quarter of 2026 Schizophrenia Teva Pharmaceuticals UZEDY Sales 2026 Forecast Medincell Royalties
BRIEF published on 07/29/2026 at 13:29, 3 months 13 days ago Ventes record pour UZEDY® au deuxième trimestre 2026 Schizophrénie Teva Pharmaceuticals Ventes UZEDY Prévisions 2026 Royalties Medincell
BRIEF published on 07/29/2026 at 13:29, 3 months 13 days ago Le partenaire de Medincell, Teva, annonce une forte croissance des ventes d'UZEDY® Croissance Des Ventes Nettes Traitement De La Schizophrénie Perspectives De Revenus Teva Pharmaceuticals Injectable À Action Prolongée
PRESS RELEASE published on 07/29/2026 at 13:24, 3 months 13 days ago Inside Information / Other news releases Teva's UZEDY® achieves record Q2 net sales of $77M, up 43% YoY. Olanzapine LAI FDA action anticipated in Q4 2026. Medincell's innovative long-acting injectable treatments show promising results Record Sales Medincell Teva UZEDY Long-acting Injectable
PRESS RELEASE published on 07/29/2026 at 13:24, 3 months 13 days ago Informations privilégiées / Autres communiqués Ventes record d'UZEDY® de 77 M$ au 2ème trimestre 2026 (+43% sur un an), Teva relève ses prévisions. Annonce sur les résultats de Teva : ir.tevapharm.com Schizophrénie Ventes Record Teva Pharmaceuticals UZEDY® Prévisions 2026
BRIEF published on 07/28/2026 at 20:26, 3 months 14 days ago Publication of the 2025/2026 Universal Registration Document by Medincell Financial Report General Assembly CSR Registration Document Medincell
Published on 11/11/2026 at 19:31, 1 hour 5 minutes ago Lion Copper Corp. Completes S-K 1300 Technical Report Summary for Bear Copper Deposit
Published on 11/11/2026 at 16:30, 4 hours 6 minutes ago ShelfieTech Announces Expansion Agreement for Its Next-Generation AI Retail Intelligence Platform
Published on 11/11/2026 at 14:25, 6 hours 11 minutes ago Route1 Announces 2026 Annual Meeting Results
Published on 11/11/2026 at 14:00, 6 hours 36 minutes ago PPX Mining Reports Callanquitas Operating Results for the First Nine Months of 2026
Published on 11/11/2026 at 14:00, 6 hours 36 minutes ago NuRAN Wireless Board Approves Growth Strategy to Scale Recurring Revenue from 5,000+ Contracted Towers
Published on 11/11/2026 at 19:29, 1 hour 7 minutes ago EQS-Adhoc: Allianz SE: Allianz delivers record nine-month result of 14.1 billion euros and raises 2026 outlook
Published on 11/11/2026 at 18:41, 1 hour 55 minutes ago AUSTRIACARD HOLDINGS AG: 9M 2026 Financial Results
Published on 11/10/2026 at 18:00, 1 day 2 hours ago Déclaration du nombre total des droits de vote et du nombre d’actions au 31 octobre 2026
Published on 11/10/2026 at 17:45, 1 day 2 hours ago Damartex / Descriptif du programme de rachat d'actions
Published on 11/10/2026 at 17:35, 1 day 3 hours ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 octobre 2026
Published on 11/10/2026 at 17:31, 1 day 3 hours ago CNP Assurances SA annonce le succès de l’émission d’une obligation subordonnée Tier 2 de 500 M€.
